CLINICAL_TRIALS
trial_result
· 2022-10-25
Clinical Trial Update: Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients [Phase 4]
Summary
Phase 4 trial update on sustained benefit of AMG334 in adults with episodic migraine. Study completed with results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Episodic Migraine | Phase 4 | Status: COMPLETED | Results posted: 2022-10-25